Scarica l'app Stockscreener
47.51
3.24%
-1.59
Dopo l'orario di chiusura:
48.12
0.61
+1.28%
Precedente Chiudi:
$49.10
Aprire:
$49.23
Volume 24 ore:
3.15M
Relative Volume:
1.51
Capitalizzazione di mercato:
$3.00B
Reddito:
$18.09M
Utile/perdita netta:
$-208.87M
Rapporto P/E:
-13.53
EPS:
-3.5125
Flusso di cassa netto:
$-178.15M
1 W Prestazione:
+2.64%
1M Prestazione:
+88.91%
6M Prestazione:
+91.50%
1 anno Prestazione:
+233.87%
Intervallo 1D:
$46.17
$49.70
Intervallo di 1 settimana:
$43.84
$50.47
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
47.51 | 3.10B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
Form 144 uniQure N.V. For: 26 June - Investing.com UK
Form 144 uniQure N.V. For: 26 June By Investing.com - Investing.com Canada
uniQure (QURE) CEO Kapusta sells 35K shares after exercising options - Stock Titan
UniQure (QURE) files Rule 144 to sell 22,402 RSU shares; prior 45,000 sold - Stock Titan
Enterprise value to EBIT forward of uniQure N.V. – NASDAQ:QURE - TradingView
uniQure N.V. Actuals & Estimates (FWB:UQ1) - TradingView
QURE Maintained by Mizuho -- Price Target Raised to $68.00 - GuruFocus
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment Gets Buy Rating - Streetwise Reports
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure N.V. Actuals & Estimates (LS:A1XDTV) - TradingView
uniQure (QURE) Is Up 6.1% After Equity Raise And FDA Backing For Accelerated HD FilingHas The Bull Case Changed? - simplywall.st
uniQure prices upsized $225M public offering of ordinary shares - MSN
Price to sales forward of uniQure N.V. – LSX:A1XDTV - TradingView
uniQure closes $259M public offering at $45.50 per share By Investing.com - Investing.com South Africa
UniQure Closes $259 Million Stock Offering - marketscreener.com
uniQure Closes $259 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure raises $259M as underwriters buy more shares - Stock Titan
Kapusta (QURE) sells 28,716 shares after option exercise on 06/25/2026 - Stock Titan
Price to earnings forward of uniQure N.V. – LSX:A1XDTV - TradingView
Price to book forward of uniQure N.V. – LSX:A1XDTV - TradingView
Enterprise value to EBIT forward of uniQure N.V. – LSX:A1XDTV - TradingView
Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight - PR Newswire UK
Mizuho raises uniQure stock price target to $68 on FDA meeting optimism - Investing.com Nigeria
UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances - Yahoo Finance
Morgan Lewis Advises uniQure on $259M Follow-On Offering – News - Morgan Lewis
uniQure Prices Upsized $225 Million Public Offering to Advance Gene Therapy Pipeline - Minichart
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $68 - Moomoo
uniQure Prices $45.50 Stock Offering; Underwriting With Leerink Partners Nets $242.7 Million - TradingView
uniQure (NASDAQ: QURE) prices $225M underwritten share offering - Stock Titan
uniQure (NASDAQ: QURE) raises $211.5M net to fund AMT-130 launch plans - Stock Titan
uniQure (NASDAQ: QURE) files Rule 144 resale notice listing recent insider sales - Stock Titan
UniQure (QURE) Gains Regulatory Support from FDA Under New Leade - GuruFocus
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
uniQure N.V. (QURE) Prices $225M Public Offering of Shares - GuruFocus
What’s next in line for FDA reversals (RGNX:NASDAQ) - Seeking Alpha
uniQure N.V. (QURE) Stock Dips Following $225M Share Offering Announcement - Blockonomi
UniQure Prices $225 Million Ordinary Stock Offering - Moomoo
uniQure prices $225M public offering at $45.50 per share By Investing.com - Investing.com Australia
QURE Raises Offering Size to $225M, Priced Below Previous Close - GuruFocus
uniQure (QURE) Shares Climb 7.6% with Notable Price Increase - GuruFocus
uniQure locks in $225M from a new share sale - Stock Titan
uniQure prices $225M public offering at $45.50 per share - Investing.com
UniQure: Granted the Underwriters 30-Day Option to Purchase Up to 741,758 Additional Shares at Public Offering Price >QURE - Moomoo
UniQure Announces Pricing of $225 Million Public Offering of Ordinary Shares - Moomoo
uniQure Announces Pricing of $225 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure Announces Pricing of Upsized $225 Million Public Offering - GlobeNewswire
Gene Therapy AMT-260 Shows Early Seizure Reductions in Refractory Mesial Temporal Lobe Epilepsy, Phase 1 Cohort Data Show - NeurologyLive
QURE Stock Soars As FDA Backs Accelerated Huntington’s Therapy Path - timothysykes.com
Barclays Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
QURE Stock Roars As FDA Clears Faster Path For AMT-130 - StocksToTrade
uniQure initiates $150 million public offering - The Pharma Letter
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):